Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Oct 16, 2021 1:31pm
171 Views
Post# 34013586

RE:RE:RE:Time to Market for H2S Pipeline

RE:RE:RE:Time to Market for H2S PipelineYou're making a huge assumption re H2S's effect on the liver. The supposed toxicity you;'re alluding to is elevated LTEs, which is a class issue with NSAIDs and indeed ALL other medications on a longer time horizon. So H2S is not at play here. 

In fact H2S has been shown to protect the liver through various mechanisms such as:

-fatty acid oxidation
-mitochondrial bioenrgetics in the heptocytes
-improvment in glucose metabloism through the electron transport chain

the list goes on.

This sell off is because of lack of upcoming catalysts, delays, and no fixed timeframes for the new indication the company is taking. In simple terms, the issue is with the management, not the science. 

Biotech ROI can be decades in many cases. People should be aware of that to adjust their risk tolerance and opportunity cost accordingly.

I would be weary of the intentions and intelleginece of posters who use hyperbolic statements like "worthless", "last nail in the coffin", "people got f*cked up", especially when making monetary decisions. 

Layth1990 wrote: Be realistic. If H2S is toxic , then all the platform is worthless .  Do not give false hopes to anyone. People got f*cked up here, leave them alone. 


<< Previous
Bullboard Posts
Next >>